Researchers from Kenya conducted a randomized controlled trial in which they administered fosfomycin, an antibiotic, in newborns with clinical sepsis. The study aimed to develop an antimicrobial regimen to treat neonatal sepsis in low and middle-income countries. Neonatal sepsis is a life-threatening condition, a blood-based bacterial infection in infants not older than 90 days. Antibiotics can manage this condition, but drug resistance to quite a few combinations has been observed.
The prevalence of this condition is highest in Sub-Saharan South African countries, affecting nearly 605,750 babies in a year and causing 302,870 deaths. Study details Neonates were screened from March 2018 to February 2019. Standard care: Ampicillin, benzylpenicillin, flucloxacillin, and gentamicin were given to all newborns. Half of the neonates randomly received additional fosfomycin intravenously and…
